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There are limited data regarding the use of angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs) in
acute heart failure (AHF). The purpose is to determine the patterns of
ACEi/ARB use at the time of admission and discharge in relation to invasive hemodynamic data, mortality, and heart failure (HF) readmissions. This is a retrospective single-center study in patients with AHF
who underwent right heart catheterization between January 2010
and December 2016. Patients on dialysis, evidence of shock, or incomplete follow up were excluded. Multivariate logistic regression
analysis was used to analyze the factors associated with continuation of ACEi/ARB use on discharge and its relation to mortality and
HF readmissions. The ﬁnal sample was 626 patients. Patients on
ACEi/ARB on admission were most likely continued on discharge. The
most common reasons for stopping ACEi/ARB were worsening renal function (WRF), hypotension, and hyperkalemia. Patients with
ACEi/ARB use on admission had a signiﬁcantly higher systemic vascular resistance (SVR) and mean arterial pressure (MAP), but lower cardiac index (CI). Patients with RA pressures above the median received
less ACEi/ARB (P = 0.025) and had signiﬁcantly higher inpatient mortality (P = 0.048). A ter multivariate logistic regression, ACEi/ARB use
at admission was associated with less inpatient mortality; OR 0.32
95% CI (0.11 to 0.93), and this e fect extended to the subgroup of
patients with HFpEF. Patients discharged on ACEi/ARB had signiﬁcantly less 6-month HF readmissions OR 0.69 95% CI (0.48 to 0.98).
ACEi/ARB use on admission for AHF was associated with less inpatient mortality including in those with HFpEF.
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1. Introduction
The inhibition of the Renin Angiotensin Aldosterone System (RAAS) plays a key role in reducing morbidity and mortality in patients with heart failure, particularly in those patients with reduced ejection fraction (HFrEF). The benefits
of the RAAS inhibition (RAASi) have been proven in landmark trials resulting in their incorporation as key elements of
guideline directed medical therapies (GDMT) for HFrEF [1–
3]. While there is less certainty on the benefits with RAASi
in patients with heart failure with preserved ejection fraction
(HFpEF), there may be a potential role in reducing hospitalizations and mortality with careful patient selection [4].
There are limited high-quality data to guide use in terms
of initiation, continuation, or withdrawal of ACEi/ARB in
the setting of acute heart failure, which is typically characterized by escalated and maladaptive activation of the RAAS [5]
regardless of underlying ejection fraction (EF). While continuation of RAASi therapy after hospital discharge in patients with HFrEF has been associated with lower mortality
and readmission rates in prior observational studies [6], there
is still a high rate of discontinuation of ACEi/ARB therapy
during AHF due to complications such as worsening kidney
function, hypotension, hyperkalemia, and angioedema [5].
Therefore, we aimed to investigate further the patterns of
ACEi/ARB use among patients with AHF, reasons for stopping these agents, hemodynamic changes associated with use,
and impact on clinical outcomes of mortality and HF readmissions.

2. Methods
2.1 Study design and patient selection
This study is a retrospective single center analysis of patients with clinical diagnosis of acute heart failure (AHF)this included patients with characteristic symptoms of shortness of breath/orthopnea/paroxysmal nocturnal dyspnea and
with clinical evidence of volume overload on physical examination as well as on imaging based on records review who
were admitted and underwent right heart catheterization
(RHC) at any point during the index admission at Einstein
Medical Center, Philadelphia between January 2010 to December 2016. We included patients that had complete hemodynamic parameters from the concomitant RHC, and information on medication use including initiation of ACEi/ARBs
during admission and discharge. We excluded patients with
end stage renal disease (ESRD) and those who presented with
hemodynamic or clinical criteria of shock (including cardiogenic shock) as these conditions reflect where the use of
ACEi/ARB or other guideline directed medical therapy for
heart failure therapy are limited see (Fig. S1). Patients who
died were excluded from the HF readmissions rate analysis.
The study protocol was approved by the local Institutional
Review Board.

bidities, EF ≥ 45%, eGFR on discharge, and the use of other
HF medications. SPSS by IBM version 23 was used for all
analyses.

Fig. 1. Rates of Inpatient Use of ACEi/ARB and Continuation on
Discharge among Patients with ACEi/ARB use at home (far left bar
graph). The rates of ACEi/ARB continued use on admission and on discharge parallel the rates of usage at home and are on the succeeding bar
graphs respectively.

2.2 Clinical data and outcome measures
De-identified demographic, clinical, and cardiac catheterization hemodynamic data were collected by review of medical records. Serum creatinine values on the day of admission and discharge were obtained; and eGFR was calculated
using the CKD-EPI equation. Heart failure with preserved
ejection fraction was defined as EF ≥ 45%. Information
on medications taken for heart failure including ACEi/ARB
use at home, on admission, and upon discharge were also
obtained. Reasons for stopping ACEi/ARBs on admission
were recorded. Clinical outcomes were identified as inpatient mortality, and HF readmissions within 1 month and 6
months.
2.3 Statistical analysis
Descriptive statistics were used to analyze the demographic and outcome variables. Chi square tests were used for
categorical variables. Demographic data were compiled and
compared between patients discharged on or off ACEi/ARBs.
Differences in hemodynamic measurements were compared
using independent t-tests among patients on ACEi/ARBs
started on admission compared to those not on these medications. For significantly different means, analysis of covariance was used to adjust for age, gender, race and ejection
fraction. Rates of HF related readmissions at 1 month and
6 months were compared between patients discharged on or
without ACEi/ARBs using Chi square. Multivariate logistic
regression analysis was used to analyze factors associated with
ACEi/ARB continuation on discharge. The multivariate logistic regression between mortality or HF readmissions and
ACEi/ARB use on discharge was performed after adjusting
for age, race, gender, diabetes, hypertension, other comor200

Fig. 2. Rates of Inpatient Use of ACEi/ARB and Continuation on Discharge among Patients not on ACEi/ARB use at home (far left bar
graph). This graph shows lower rates of ACEi/ARB use on admission and
on discharge among those not originally on ACEi/ARB at home.

3. Results
3.1 Patient demographics
Of the final sample of 626 patients see (Fig. S1), mean age
(+/-SD) was 66.92 ± 13.63 years old. 48.1% were females;
58.1% were African Americans and 31.2% were Caucasians.
61% of subjects had an ejection fraction (EF) ≥ 45%. RHC
was done for worsening heart failure for 66% of patients, 13%
for valvular heart disease evaluation, 9% for evaluation of ischemia, 5% for evaluation of pulmonary hypertension and 6%
for other reasons such as intracardiac shunt evaluation, pericardial tamponade, transplant evaluation and worsening renal function (see Fig. S2). Demographic and baseline clinical
data in Table 1 contrast patients discharged on ACEi/ARBs
to those off ACEi/ARBs.
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below the median values of PCWP and RAP as these were the
hemodynamic parameters that coincide with signs and symptoms of AHF. There were no significant differences in patients with PCWP values above or below the median in terms
of ACEi/ARB use P = 0.688 and inpatient death P = 0.430.
However, when we examined patients with RAP above or
below the median of 11 mmHg in our sample population, patients who had RAP above the median had significantly less
ACEi/ARB use on admission 130 vs 150 P = 0.025 and had
significantly higher rates of inpatient death 18 vs 8 P = 0.048
(see Fig. 4).
3.4 Clinical outcomes associated with ACEi/ARB use
Fig. 3. Reasons for Stopping ACEi/ARB on Admission with AKI and
hypotension as the leading causes.

3.2 Patterns of ACEi/ARB use
There were 298 (47.6%) patients that were on ACEi/ARBs
at home prior to admission. Eighty percent of patients on
ACEi/ARB were continued on these agents on admission and
77% were discharged on it (Fig. 1). In the other hand, 328
patients were not on ACEi/ARB at home. 42 (13%) patients
were started newly on ACEi/ARB on admission and 85 (26%)
of these patients were discharged on ACEi/ARBs (Fig. 2).
Among those on ACEi/ARB at home and those newly started
during the hospitalization, majority of the reasons for discontinuation were worsening renal function (WRF) (60%), hypotension (31%), and hyperkalemia (2%) (Fig. 3).
Independent factors associated with continuation of
ACEi/ARBs on discharge were analyzed using multivariate
logistic regression analysis. Existing ACEi/ARB use at home
was highly associated with ACE/ARB on discharge OR 9.68
95% CI (6.36-14.76). Higher eGFR on discharge was also correlated with ACEi/ARB use on discharge OR 1.014 95% CI
(1.008 to 1.021). Ejection fraction (EF) was inversely associated with continuation of ACEI/ARB wherein higher EF
was associated with less odds of ACEi/ARB use on discharge
OR 0.96 95% CI (0.946 to 0.972). Racial minority (nonAfrican American, non-Caucasian or non-Hispanic ethnicity) also predicted less ACEi/ARB on discharge OR 0.3 95%
CI (0.101- 0.897) (Table 2).

There were 26 recorded-inpatient deaths in this cohort.
39% were from acute coronary syndromes, 23% were from
respiratory arrest related to heart failure, 19% were from
heart failure with multiorgan failure, 15% were from arrhythmias and 4% were non-cardiac causes. After adjusting for demographics and baseline comorbidities, patients who were
on ACEi/ARB at home had a significantly lower odds of inpatient mortality OR 0.32, 95% CI (0.11 to 0.93) (see Table
S1). In a subgroup analysis looking at patients with HF with
preserved EF (HFpEF), patients on ACEi/ARB had lower
inpatient deaths compared to those without (1.3% vs 5.4%
P = 0.037). On multivariate logistic regression, ACEi/ARB
use among patients with HFpEF was still significantly associated with lower inpatient mortality OR 0.10, 95% CI (0.01 to
0.908) P = 0.041 (see Table S2).

3.3 Hemodynamic parameters associated with ACEi/ARB use
The right atrial pressures (RAP) were elevated in both
groups (on ACEi/ARB vs no ACEi/ARB) with mean of 12.05
± 6.96 mmHg and mean pulmonary artery pressures were
elevated with mean of 31.82 ± 11.6 mmHg. Pulmonary
capillary wedge pressure (PCWP) was also elevated at 19.93
± 8.81 however, there were no significant differences between these pressures in those with ACEi/ARB vs those
without. The mean transpulmonary gradient was within
borderline range at 12 mmHg. Patients on ACEi/ARB on
admission were found to have significantly higher SVR and
MAP, but lower cardiac index compared to those who were
off ACEi/ARB see Table 3. We looked at patients above and
Volume 22, Number 1, 2021

Fig. 4. ACEi/ARB use and Inpatient Mortality Stratified by Median
RA pressure showing that among patients with higher RA pressure
above the median, there was a significantly lower rates of continued
ACEi/ARB use but higher rates of inpatient death.

Among those who survived and were discharged without
ACEi/ARB in the full cohort, 136 (22.7%) were readmitted
within 1 month and 255 (42.5%) were readmitted within 6
months. There was a significantly lower rate of 1-month
HF readmission among patients discharged on ACEi/ARB
201

Table 1. Demographic and Clinical Characteristics of Patients.
Discharge with ACE/ARB (n = 314)

OFF ACE/ARB (n = 312)

P value

65.54 ± 13.23

68.31 ± 13.92

0.01

168 (53.5)
146 (46.5)

157 (50.3)
155 (49.7)

0.472

64.6
26.4

51.6
35.9

< 0.0001

6.7
2.2
149 (47.6)
286 (91.4)
143 (45.5)
67 (21.3)

4.8
7.7
155 (50)
266 (85.8)
143 (46.1)
78 (25.2)

0.575
0.032
0.936
0.297

116 (37.5)
143 (45.5)
32.89 ± 14.32
73.60 ± 29.93
74.72 ± 28.38

95 (31)
238 (76.3)
32.41 ± 15.49
58.33 ± 32.90
59.85 ± 36.22

0.106
< 0.0001
0.875
0.024
0.001

229 (72.9)
257 (82)
232 (52.3)
78 (25)
63 (20)
33 (10.5)

69 (22.1)
228 (73)
212 (47.7)
66 (21.3)
71 (23)
19 (6.1)

< 0.0001
0.01
0.141
0.296
0.436
0.059

53 (17)

23 (7.4)

< 0.0001

Mean Age (years old ± SD)
Gender
Male, n (%)
Female, n (%)
Race
African American, n (%)
Caucasian, n (%)
Hispanic, n (%)
Others, n (%)
Diabetes, n (%)
Hypertension, n (%)
Coronary Artery disease, n (%)
Atrial fibrillation, n (%)
Smoking, n (%)
Ejection fraction EF ≥ 45%
BMI
eGFR on admission
eGFR on discharge
Medications used (%)
ACE/ARB
Beta blocker use
Diuretics
Nitrates
Hydralazine
Digoxin
MRA

Table 2. Multivariate Logistic Regression on Predictors of
ACE/ARBs Use on Discharge.
OR

95% CI

P value

Age
Male
Female
African American
Caucasian

0.999
Referrant
1.309
Referrant
0.677

0.982 to 1.015

0.863

0.854 to 2.005

0.216

0.424 to 1.082

0.103

Hispanic
Others
eGFR on discharge
EF
Diabetes
Hypertension

0.697
0.301
1.014
0.958
0.721
1.175

0.290 to 1.674
0.101 to 0.897
1.008 to 1.021
0.946 to 0.972
0.475 to 1.095
0.607 to 2.273

0.419
0.031
< 0.0001
< 0.0001
0.125
0.633

On ACEi/ARB at home

9.684

6.355 to 14.759 < 0.0001

(23.6% vs 36.2%) P = 0.032 while 6-month HF readmission
rates were borderline significant (38.9% vs 46.5%) P = 0.069.
In analysis of a composite of 6-month readmissions and inpatient mortality, those with RA pressure above the median
and without ACEI/ARB had significantly higher number of
poor outcomes 55% vs 38% P < 0.001 compared to those on
an ACEI/ARB see Fig. 5.
After adjusting for age, gender, comorbidities, eGFR at
discharge and HF medication use, ACEi/ARB on discharge
was associated with lower rates of 6-month HF readmission
202

Fig. 5. Outcomes of inpatient death and 6 month readmissions stratified by ACEi/ARB use and RA pressure above or below the median.
This figure shows more rates of inpatient death and 6 month readmissions
in the subset with both RA pressure above the median and at the same time
not on ACEi/ARB.

OR 0.69 95% CI (0.48 to 0.98) and borderline significant
for 1-month HF readmission OR 0.66 (0.44 to 1.02) (Tables
S3,4).
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Table 3. Hemodynamic Parameters Associated with ACE/ARB Use on Admission.
Hemodynamics (mean ± SD) in mmHg

ACE/ARB on admission (n = 346)

OFF ACE/ARB (n = 280)

P value

11.71 ± 6.78

12.33 ± 7.09

0.264

mPAP
PCWP
Transpulmonary gradient
PVR (dynes-sec-cm-5)
SVR (dynes-sec-cm-5)
SVR adjusted (Standard error)

31.7 ± 11.32
19.88 ± 8.58
12.18 ± 8.23
224.99 ± 161.53
1598.31 ± 664.68
1573 (38.06)

31.92 ± 11.84
19.98 ± 9.01
12.29 ± 9.47
223.49 ± 204.59
1431.94 ± 629.39
1459 (34.24)

0.816
0.892
0.882
0.921
0.002
0.027

MAP
MAP adjusted (Standard error)
CI
CI adjusted (Standard error)

96.32 ± 17.25
96.34 (0.99)
2.22 ± 0.76
2.24 (0.056)

91.07 ± 16.77
91.34 (0.90)
2.48 ± 1.06
2.47 (0.050)

< 0.0001
< 0.0001
0.001
0.003

RA pressure

4. Discussion
Our study found that ACEi/ARB use was associated with
significantly lower inpatient mortality as well as lower 6
month HF readmission rates among patients admitted with
AHF. This mortality benefit also extended to the subgroup
of patients with HFpEF with acute HF exacerbation. While
the clinical benefits in the use of ACEi/ARB for patients with
chronic HFrEF are well established [2, 3], there are less highquality data guiding the management of RAASi in patients
admitted with acute HF. This results in marked heterogeneity in clinical practice with respect to continuation, escalation
or cessation of RAASi in acute HF in patients with HFrEF [5].
There is also less evidence supporting routine use of RAASi
in patients with chronic HFpEF, which remains difficult to
treat due to its different phenotype and unique multifactorial pathophysiology [7–11]. Various studies have shown
that ACEi/ARB mainly showed benefits in reduced HF hospitalizations, but no significant effect on all-cause mortality
and cardiovascular mortality [9–11]. However, in a metaanalysis, the use of ACEI in HFpEF showed an all-cause mortality benefit (RR = 0.91, 95% CI = 0.87-0.95) [4]. Several
factors may contribute to the lack of demonstrable benefits
with RAASi in HFpEF including the lack of a clear consensus on the definition of HFpEF which can lead to significant
heterogeneity in clinical profiles, exercise capacity, and relevant clinical end points [12]. It should also be noted that
the major trials looking at ACEi/ARB in patients with HFpEF were not done in the setting of AHF [9–11]. In an
analysis of the DOSE-AHF (Diuretic Optimization Strategies in Acute Heart Failure) and CARRESS-HF (Cardiorenal Rescue Study in Acute Decompensated Heart Failure) trials [13, 14] by Mentz et al., although patients with HFpEF
tended to have lower baseline aldosterone levels compared
to HFrEF, biomarkers for RAAS activation (plasma renin activity and serum aldosterone levels) were nevertheless elevated [15], suggesting that at least in AHF, there is a similar mal-adaptive activation of the RAAS. This provides plausibility to the hypothesis that RAASi may be beneficial in
AHF with potential to modify the vulnerable post hospitalization course regardless of underlying EF. In addition to the
Volume 22, Number 1, 2021

effects of ACEi/ARBs directly on the RAAS system, ACEi
were also shown to decrease inflammatory chemokines such
as interleukins that may be useful in targeting the inflammatory pathway of heart failure and cardiorenal syndrome
[16]. ACEi inhibit bradykinin breakdown which may have
actions including vasodilation, fibrinolysis, and inhibition of
cell growth that may contribute to its HF benefits but at the
same time side effects such as cough and angioedema [17].
Meanwhile, angiotensin type I receptor blockade with ARBs
can lead to more angiotensin II receptor stimulation which
also has vasodilatory and antiproliferative effects that may
be beneficial with less associated adverse effects from the
bradykinin system [17, 18]. However, whether clinical outcomes among patients who received ACEi vs ARBs were different in this analysis due to plausible neurohormonal effects
and/or any component of the effects of ACEi/ARB on the
inflammatory pathway in HF needs further study.
Serial measurements by Packer et al. showed that ACEi
acutely lowered right and left ventricular filling pressures,
mean arterial pressure, heart rate, systemic and pulmonary
vascular resistance in severe HF. RAASi decreases preload
and afterload through blocking vasoconstrictive effect of angiotensin II [19]. However, hemodynamic parameters in
our study revealed patients in AHF (in the absence of cardiogenic shock) and on ACEi/ARB therapy had significantly
higher mean SVR and MAP, and lower cardiac index compared to those not on these medications. Although temporal
relationships between these hemodynamic parameters and
ACEi/ARB use could not be established in this study, patients in AHF usually have precipitating factors that lead to
decompensation. Especially in patients with HFpEF, higher
blood pressure reflecting a higher SVR and afterload may
trigger AHF wherein ACEi/ARB use is appropriate and potentially therapeutic [20]. We also found that patients with
RAP above the median received less ACEi/ARB but had significantly higher rates of inpatient mortality and readmissions. This is consistent with previous studies that an elevated central venous pressure or right atrial pressure was directly associated with renal outcomes and all-cause mortality
in patients with cardiovascular disease [21, 22]. These find203

ings also suggest that there is really no standardized clinical
guidance on the use of ACEi/ARB in patients with AHF and
oftentimes, these medications are suspended. These patients
with high right atrial pressure likely have concomitant cardiorenal syndrome [23] and that these findings reflect a reflexive tendency of clinicians to indiscriminately stop these
agents due to concerns for WRF, despite the potential for
optimizing the neurohormonal changes seen with acute HF
with the use of these drug classes.
The main reasons for ACEi/ARB discontinuation in our
study were azotemia (60%), hypotension (31%), and hyperkalemia (2%). Our findings are consistent with multiple prior
studies have described same factors for withdrawal or as barrier for initiation of RAASi [5, 6, 24, 25]. Perceived risk for
or real decline of renal function is one of the common triggers for RAASi withdrawal in clinical practice. However,
elevation of serum creatinine and BUN to a greater extent
in AHF likely only reflect hemodynamic changes in the setting of cardiorenal syndrome, and not necessarily intrinsic
renal damage [26]. Elevated right sided filling pressures (as
what was seen in our sample population), translating to elevated renal venous pressures and subsequent decreased renal
blood flow, coupled with elevated levels of RAAS and neurohormonal activation leading to preglomerular vasoconstriction may lead to the reduced GFR characteristic of cardiorenal syndrome [23]. This pathophysiologic condition actually
benefits from careful ACEi/ARB administration rather cessation. In the CONSENSUS trial, there was a marked reduction in HF-associated mortality and symptom burden [3] and
that trends of rise in serum creatine were mostly during early
phase and returned within 30% of baseline thereafter [27].
A meta-analysis by Flather et al. on ACEi in AHF showed
that discontinuation was rarely necessary despite higher rates
of azotemia in the treatment versus placebo arms [28]. The
critical need to ensure optimal delivery of ACEi/ARB, especially during and after vulnerable period of AHF despite elevation of serum creatinine, are missed opportunities to improve clinical outcomes with these patients [5].
In the setting of WRF and AHF, biomarkers of intrinsic kidney injury are valuable in clinical decision-making on
RAASi use [23]. Validated biomarkers of tubular injury,
urine microscopy and urinary sediment analysis are simple
and readily available tests to distinguish intrinsic AKI (typically with superimposed sepsis or shock) from functional
changes in serum creatinine [5, 23]. The use of commercially
available biomarkers of tubular injury such as serum and
urine NGAL (neutrophil gelatinase-associated lipocalin), and
the combination of TIMP-2 and IGFBP7 (tissue inhibitor of
metalloproteinase-2 and insulin-like growth factor-binding
protein 7 respectively) can detect early intrinsic tubular injury and may play a role when they are negative in ensuring appropriate continuation of RAASi in the setting of AHF
despite benign fluctuations in markers of glomerular injury
such as serum cystatin and serum creatinine [29, 30].
Hyperkalemia is another legitimate yet infrequent reason
204

for discontinuation of ACEi/ARB in this study. Collins et al.
demonstrated that the presence of HF considerably increased
fatal risks of hyperkalemia in patients on RAASi therapy [31].
In the Hyperkalaemia Randomized Intervention Multidose
SZC Maintenance (HARMONIZE) trial, a subgroup analysis in patients with HF and hyperkalemia showed that use
of sodium zirconium cyclosilicate achieved normokalemia
in 93% of patients within 48-h without the need to adjust the RAASi doses [32]. Hence, the use of novel oral
anti-hyperkalemic agents such as sodium zirconium cyclosilicate or patiromer can prove as valuable tools in optimizing
ACEi/ARBs use in AHF [33, 34].
Finally, contextual prescription patterns seem to be a factor in the continuation of ACEi/ARB use in AHF. Our study
found that independent of baseline co-morbidities, prior usage was a factor that is strongly associated with discharge
therapy of ACEi/ARB. The same pattern of use was reported
in a large observational data using Get With the GuidelinesHeart Failure (GWTG-HF) registry, to which 88.5% usage
of ACEi/ARB prior to hospitalization persisted from admission through discharge of AHF in those with reduced EF [35].
Physician reluctance to alter a patient’s existing medical regimen may have contributed to these findings [35]. Continued physician and provider education about the benefits of
continuation of ACEi/ARB is warranted to achieve improved
outcomes in AHF.

5. Strengths and limitations
Our study has all the limitations of a retrospective and
single-center analyses. Data were collected from electronic
medical records and some laboratory values such as the actual potassium levels were not provided and included as part
of the analyses. The temporal relationships between the
invasive hemodynamic parameters and use of ACEi/ARBs
cannot fully be established. Data on whether ACEi/ARBs
were stopped midway during the course of admission was
not available and may potentially influence some clinical outcomes. ACEi/ARBs were also analyzed together and differences in the mechanism and relation of ACEi compared to
ARB in heart failure and cardiorenal syndrome pathophysiology may also influence outcomes. Overall patient compliance
to GDMT was not assessed. The specific doses used for each
individual ACEi/ARBs were not considered in this analysis. Compliance with the other components of the guidelinedirected medical therapy for heart failure was not a part of
the scope of this study but were partly accounted for their
effect in the multivariate analyses of the outcomes. Use of
other anti-hypertensive medications such as calcium channel
blockers and centrally acting agents were not accounted for
and may influence blood pressure and heart failure outcomes.
Our institution predominantly serves patients from the low
socio-economic stratum, compliance to GDMT and diuretics is a limitation. Time to diuretic use on admission was
also not documented. Nevertheless, this study has a reasonably large sample size with females (48%) and African AmeriVolume 22, Number 1, 2021

cans (58%) adequately represented. These are the population
groups who are usually under-represented in cardiovascular
studies [36]. This study is also the first to our knowledge to
explore hemodynamic parameters in relation to ACEi/ARB
use and quantify evidence that use of ACEi/ARB in the setting of AHF can have clinical benefits across strata of ejection
fraction.

[3]

[4]

6. Conclusions
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Patients on ACEi/ARB at home are most likely to continue these medications on admission and upon discharge
after AHF. Most common causes cited for withdrawal of
RAASi while in-hospital were WRF, hypotension, and hyperkalemia. ACEi/ARB use on admission was associated
with significantly less inpatient mortality while ACEi/ARB
on discharge was associated with less 6-month HF readmissions, including in patients with HFpEF.
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